Philips and Akumin Partner

Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Akumin Inc., a leading provider of outpatient diagnostic imaging services in the U.S., today announced a strategic collaboration to deploy Philips’ new Radiology Operations Command Center across Akumin’s outpatient imaging centers and co-create clinical standards for Akumin’s MR and CT imaging modalities.

Designed to centralize, virtualize, and standardize network-wide imaging operations while facilitating secure remote access, Philips’ vendor-agnostic command center broadens the scope of collaboration and expertise sharing between technologists, radiologists and imaging operations teams across multiple sites – capabilities that fit perfectly into Akumin’s networked imaging center model. Akumin, which currently operates over 130 outpatient imaging centers across seven U.S. states, is Philips’ first large-scale commercial Radiology Operations Command Center customer in North America.

“We are very excited to partner with Philips on this important strategic initiative to standardize the delivery of clinical care to our patients, while ensuring business continuity, improving ‘first time’ image quality, and increasing our clinical personnel productivity”, said Riadh Zine, President & CEO of Akumin.

“Addressing radiology pain points such as operator variability, training, and the need to standardize and optimize image quality, Radiology Operations Command Center is Philips’ latest innovation in quality and productivity improvement,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “Deploying Philips Radiology Operations Command Center across Akumin’s center-of-excellence imaging network is the perfect opportunity to further drive radiology workflow efficiency to improve patient outcomes, enhance patient and staff experiences, and reduce the cost of care.”

Leveraging the capabilities of the command center, Philips and Akumin aim to establish best-practice clinical standards for Akumin’s MRI and CT modalities to enable a consistent approach to imaging procedures across the Akumin platform. It will also allow Akumin to implement centralized tailored support for individual imaging centers to improve their on-site clinical expertise. 

Philips’ integrated, data-driven radiology workflow solutions connect people, data and technology to advance precision diagnosis and create clear care pathways that lead to predictable outcomes. For example, Philips Radiology Operations Command Center allows technologists and radiologists to have a real-time ‘virtual’ telepresence in any connected MR or CT console room to contribute expertise, guidance and training in acquiring right-first-time images. Its ability to centrally monitor every MR and CT scanner in a network from a single location and orchestrate workflows helps to maintain business continuity, increase enterprise-wide radiology productivity, minimize issues with image quality, and expand access to advanced MR- and CT-based diagnosis.

The Philips Radiology Operations Command Center is the latest addition to Philips’ end-to-end Radiology Workflow Suite, which helps drive clinical and operational efficiency across all phases of the diagnostic enterprise, including patient scheduling and preparation (Patient Management), image acquisition (Radiology Operations Command Center, Collaboration Live, MR Smart Workflow, Radiology Imaging Suite), image and data interpretation (Workflow Orchestrator, Advanced Visualization Workspace – IntelliSpace Portal), reporting (Clinical Collaboration Platform), decision-making, pathway selection and treatment (Tumor Multidisciplinary Team Orchestrator), and follow-up care (Enterprise Performance Suite). The Philips Radiology Operations Command Center supports legacy systems as well as state of the art technology including Philips newest innovation, the spectral detector-based Spectral Computed Tomography (CT) 7500, to expand access to novel imaging across the enterprise.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version